Post-earnings recap
Reported
Mon, Feb 9, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Arrowhead Pharmaceuticals is facing challenges, as evidenced by the EPS miss. The stock reacted negatively, dropping 2.82%, reflecting investor concerns about the company's current performance and lack of guidance. Without specific revenue figures or future outlook, investors may remain cautious in the near term.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.41 | N/A | -30.16% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed caution regarding current performance. They highlighted ongoing challenges but maintained a focus on future objectives.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term goals despite short-term setbacks.